ATE155037T1 - Verwendung von eicosapentaensäure zur behandlung der kachexie - Google Patents

Verwendung von eicosapentaensäure zur behandlung der kachexie

Info

Publication number
ATE155037T1
ATE155037T1 AT90904918T AT90904918T ATE155037T1 AT E155037 T1 ATE155037 T1 AT E155037T1 AT 90904918 T AT90904918 T AT 90904918T AT 90904918 T AT90904918 T AT 90904918T AT E155037 T1 ATE155037 T1 AT E155037T1
Authority
AT
Austria
Prior art keywords
lipolytic
mammals
polyunsaturated fatty
activity
cachexia
Prior art date
Application number
AT90904918T
Other languages
English (en)
Inventor
Michael John Tisdale
Susan Anne Beck
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Application granted granted Critical
Publication of ATE155037T1 publication Critical patent/ATE155037T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Fats And Perfumes (AREA)
AT90904918T 1989-03-20 1990-03-20 Verwendung von eicosapentaensäure zur behandlung der kachexie ATE155037T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898906369A GB8906369D0 (en) 1989-03-20 1989-03-20 Eicosapentaenoic acid
SG137193A SG137193G (en) 1989-03-20 1993-12-21 Eicosapentaenoic acid

Publications (1)

Publication Number Publication Date
ATE155037T1 true ATE155037T1 (de) 1997-07-15

Family

ID=26295116

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90904918T ATE155037T1 (de) 1989-03-20 1990-03-20 Verwendung von eicosapentaensäure zur behandlung der kachexie

Country Status (11)

Country Link
EP (1) EP0464084B1 (de)
JP (1) JP3010310B2 (de)
AT (1) ATE155037T1 (de)
AU (1) AU643201B2 (de)
DE (1) DE69031033T2 (de)
DK (1) DK0464084T3 (de)
ES (1) ES2103738T3 (de)
GB (2) GB8906369D0 (de)
HK (1) HK2894A (de)
SG (1) SG137193G (de)
WO (1) WO1990011073A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2112399C (en) * 1991-06-24 2004-06-29 Antonio Ferrante Methods and compositions for treating malaria and other diseases
DE4304394A1 (en) * 1993-02-13 1993-09-02 Fresenius Ag Prepn. for nourishment of oncological patients - comprises fats formulation contg. oleic acid, alpha-linolenic acid, etc., and opt. carbohydrate and proteins
CA2119000A1 (en) * 1993-03-19 1994-09-20 David Frederick Horrobin Formulation for use in smokers
ATE236627T1 (de) 1996-10-11 2003-04-15 Scarista Ltd Pharmazeutische zubereitung enhaltend eicosapentaensäure und/oder stearidonsäure
JP3017151B2 (ja) 1997-11-26 2000-03-06 静岡日本電気株式会社 携帯装置のハンドストラップとこのハンドストラップの取付構造
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
SK14502003A3 (en) * 2001-05-30 2004-10-05 Laxdale Ltd Coenzyme Q and eicosapentaenoic acid
US20050215640A1 (en) * 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
EP2025248A1 (de) * 2007-07-31 2009-02-18 Fresenius Kabi Deutschland GmbH Zubehör zur Verhinderung von Abmagerungen
WO2009149496A1 (en) * 2008-06-10 2009-12-17 Central Northern Adelaide Health Service Treatment of diabetes and complications thereof and related disorders
EP2334295B1 (de) 2008-09-02 2017-06-28 Amarin Pharmaceuticals Ireland Limited Pharmazeutische zusammensetzung mit eicosapentaensäure und nikotinsäure und anwendungsverfahren dafür
SI2395991T1 (sl) 2009-02-10 2013-12-31 Amarin Pharmaceuticals Ireland Limited Uporaba etil estra eikozapentaenojske kisline za zdravljenje hipertrigliceridemije
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
SG10201605794PA (en) 2009-04-29 2016-09-29 Amarin Pharmaceuticals Ie Ltd Stable Pharmaceutical Composition And Methods Of Using Same
EP3318255B1 (de) 2009-06-15 2021-03-10 Amarin Pharmaceuticals Ireland Limited Zusammensetzungen und verfahren zur behandlung des schlaganfalles bei patienten mit gleichzeitiger statin-therapie
AU2010298222B2 (en) 2009-09-23 2017-01-05 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
NZ727849A (en) 2012-06-29 2018-06-29 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US20200085774A1 (en) * 2016-12-23 2020-03-19 Basf As Omega-3 Fatty Acid Composition for Preventing and/or Treating Cachexia
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
LT3750536T (lt) 2018-09-24 2026-03-25 Amarin Pharmaceuticals Ireland Limited Širdies ir kraujagyslių sistemos reiškinių rizikos subjekto organizme sumažinimo būdai
BR112022009189A2 (pt) 2019-11-12 2022-07-26 Amarin Pharmaceuticals Ie Ltd Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0106571A3 (de) * 1982-09-22 1984-07-25 Sentrachem Limited Prophylaktische Substanz oder Komposition
AU4595985A (en) * 1984-08-10 1986-02-13 Sentrachem Limited Cancer treatment
JPS63303925A (ja) * 1987-06-05 1988-12-12 Nippon Oil & Fats Co Ltd 制癌剤組成物
GB8806471D0 (en) * 1988-03-18 1988-04-20 Tisdale M J Biologically active material characterised by catabolic activity generally associated with cachexia inducing tumours
GB2223943A (en) * 1988-10-21 1990-04-25 Tillotts Pharma Ag Oral disage forms of omega-3 polyunsaturated acids
DE3901048A1 (de) * 1989-01-14 1990-07-19 Chimicasa Gmbh Antikachectikum
CA2010511A1 (en) * 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids

Also Published As

Publication number Publication date
GB2229363A (en) 1990-09-26
GB8906369D0 (en) 1989-05-04
WO1990011073A1 (en) 1990-10-04
DE69031033T2 (de) 1997-11-20
AU643201B2 (en) 1993-11-11
DK0464084T3 (da) 1997-08-11
DE69031033D1 (de) 1997-08-14
HK2894A (en) 1994-01-21
GB2229363B (en) 1993-06-02
EP0464084A1 (de) 1992-01-08
GB9006256D0 (en) 1990-05-16
EP0464084B1 (de) 1997-07-09
JPH05504936A (ja) 1993-07-29
AU5331090A (en) 1990-10-22
SG137193G (en) 1994-03-31
ES2103738T3 (es) 1997-10-01
JP3010310B2 (ja) 2000-02-21

Similar Documents

Publication Publication Date Title
ATE155037T1 (de) Verwendung von eicosapentaensäure zur behandlung der kachexie
DE69003652D1 (de) Verwendung von c-22 bis c-26-aliphatischen alkoholen zur behandlung entzuendlicher und viraler hauterkrankungen.
DE69822832D1 (de) Therapeutische und lebensmittel-zusammensetzungen, welche essentielle fettsäuren und bioaktive disulfide enthalten
DK308684A (da) Enzympraeparat til rensningsformaal
ATE186834T1 (de) Verwendung von wirksamen mengen von aktiven stoffen zur behandlung von mischhaut
DE69632236D1 (de) Verwendung von dha in der behandlung von dyslexie
ATE43242T1 (de) Pharmazeutische oder diaetetische zusammensetzung mit hoher antithrombotischer und antiarteriosklerotischer wirkung.
DE3588023D1 (de) Mittel zur Behandlung von Herzerkrankungen.
NO850391L (no) Preparater for kosmetisk, helse- og kroppskonserverende bruk
ATE222101T1 (de) Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
JP2006522074A (ja) セルライトを防止し処理するための構成物
US5891083A (en) Suction lipolysis
DE69317716D1 (de) Verwendung von Fettsäuren zur Behandlung von abnormalen Verkalkung des Gewebes
Arthur et al. Experimental evidence for an enzymatic basis for itching in man
DE3878812D1 (de) Omega-3-fettsaeuren zur behandlung von traumatischen verwundungen.
CA2052577A1 (en) Therapeutic uses of eicosapentaenoic acid
SE8800990D0 (sv) Skin-regenerating cosmetic compositon and process for preparing same
RU2123320C1 (ru) Крем для кожи лица "talita"
DE60325383D1 (de) Antipyretikum und herstellungsverfahren dafür
RU2040251C1 (ru) Косметическое средство р.н.караева для ухода за кожей лица и тела
KR20220016318A (ko) 관절 염증 개선 및 연골 보호를 위한 홍합 추출유 복합물 및 크릴 추출유를 포함하는 조성물
RU97119835A (ru) Крем для кожи лица и тела
RU96117923A (ru) Способ лечения хронических сальпингоофоритов
KR950005917B1 (ko) 솔잎 추출물〈pine essential oil, pine absolute 및 pine concrete〉을 첨가한 미용 비누
UA10281C2 (uk) Спосіб отримання речовини для лікування захворювань підшлункової залози

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee